Skip to search formSkip to main contentSkip to account menu

TCV 309

Known as: TCV-309 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Platelet Aggregation InhibitorsPyridinium CompoundsTetrahydroisoquinolines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
Contribution of platelet activating factor to myocardial ischemia-reperfusion injury
Myocardial ischemia-reperfusion (MIR) injury, which occurs during events such as myocardial infarction (MI) treated with… 
1995
1995
Donor pretreatment with PAF antagonist TCV-309 enhances lung preservation
1995
1995
Efficacy of a platelet-activating factor antagonist TCV-309 for lung preservation
1994
1994
The effect of platelet‐activating-factor antagonist TCV‐309 on arrhythmias and functional recovery during myocardial reperfusion
BackgroundWe investigated the effects of a platelet-activating-factor antagonist TCV-309, an antagonist of metabolites of… 
1994
1994
The Efficacy of PAF Antagonist TCV-309 in a Canine Single Lung Allotransplantation after 24 hour . Preservation
Title The Efficacy of PAF Antagonist TCV-309 in a Canine Single Lung Allotransplantation after 24 hour . Preservation Author(s… 
1994
1994
Efficacy of a Platelet-Activating Factor Antagonist TCV-309 for Lung Preservation
To evaluate the efficacy of a platelet-activating factor (PAF) antagonist, TCV-309, for the prevention of lung reperfusion injury… 
1992
1992
SJKonturek, ADembinski, PJKonturek, ZWarzecha, JJaworek, PGustaw, RTomaszewska,
Theimportance ofplatelet activating factor in acute pancreatitis wasexamined bydeterminingthetissue content ofendogenous platelet… 
1991
1991
TCV-309 - A NOVEL PAF-ANTAGONIST, INHIBITS PAF-INDUCED HUMAN PLATELET-AGGREGATION EXVIVO
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)